NovoSeven 1 mg/vial IV Injection

NovoSeven 1 mg/vial IV Injection Uses, Dosage, Side Effects, Food Interaction and all others data.

NovoSeven 1 mg/vial IV Injection
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	NovoSeven 1 mg/vial IV Injection
Generic	Coagulation Factor VIIa [Eptacog Alfa]
Weight	1 mg/vial
Type	IV Injection
Therapeutic Class	Anti-fibrinolytic drugs
Manufacturer	Novo Nordisk
Available Country	Bangladesh
Last Updated:	September 24, 2024 at 5:38 am

Uses

Coagulation Factor VIIa is indicated in Bleeding episodes in patients with haemophilia, Bleeding episodes due to surgery or invasive procedures in patients with factor VII deficiency, Bleeding episodes due to surgery or invasive procedures in Glanzmann's thrombasthenia

Dosage

NovoSeven 1 mg/vial IV Injection dosage

Bleeding episodes in patients with haemophilia: Adult:As activated eptacog alfa: Initially, 90 mcg/kg given via IV bolus over 2-5 min. Additional dose may be given as needed to achieve or maintain haemostasis, initially 2-3 hrly. May adjust dose or dosing interval according to response. May continue therapy for up to 3 wk or more in cases of serious bleeding episodes. Bleeding episodes due to surgery or invasive procedures in patients with factor VII deficiency: Adult:As activated eptacog alfa: 15-30 mcg/kg 4-6 hrly via IV bolus over 2-5 min until haemostasis is achieved. Bleeding episodes due to surgery or invasive procedures in Glanzmann's thrombasthenia: Adult:As activated eptacog alfa: 90 mcg/kg 2 hrly via IV bolus over 2-5 min, give at least 3 doses.

Side Effects

Nausea, vomiting, skin reactions, fever, headache and changes in BP. Rarely, anaphylaxis.

Precaution

Advanced atherosclerotic disease, crush injury, septicemia or disseminated intravascular coagulation. Patients w/ history of CHD, liver disease, undergoing major surgery, at risk of thromboembolic phenomena or disseminated intravascular coagulation. Remote possibility of hypersensitivity to mouse IgG, bovine IgG & other residual culture proteins. Monitor prothrombin time & factor VII coagulant activity in factor VII deficient patients. Pregnancy & lactation. Neonates.

Interaction

Increased risk of thromboembolism with activated or non-activated prothrombin complex concentrate.

Pregnancy & Breastfeeding use

It is preferable to avoid use during pregnancy. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.It is unknown whether eptacog alfa is excreted in human breast milk. The excretion of eptacog alfa in milk hasnot been studied in animals.

Contraindication

Hypersensitivity to recombinant coagulation factor VIIa or to mouse, hamster or bovine protein. Rare hereditary problems of fructose intolerance, glucose malabsorption or sucrose-isomaltase insufficiency.